Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer

Overview of attention for article published in Frontiers in oncology, September 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,531 followers.

New research: Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer: Background Zimberelimab (GLS-010) is a novel fully human monoclonal immunoglobulin G4 (IgG4) against… https://t.

15 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.